Taro down 4% after FQ3 report, continued sales headwinds

Taro Pharmaceutical Industries (TARO -4%) fiscal Q3 results:

Sales: $147.7M (-16.3%). Shortfall due to competition, especially in U.S. generics.

Net income: $67.7M (-27.6%); EPS: $1.76 (-26.7%).

Cash flow ops (9 mo.): $222.0M (-16.3%).

Taro Pharmaceutical EPS beats by $0.22, misses on revenue 

https://seekingalpha.com/news/3537996-taro-down-4-after-fq3-report-continued-sales-headwinds